



INCANTHERA PLC

26 NOVEMBER 2024

Ticker	INC
Share price	14p
Market cap	£16m

Company description

Founded as a spin-out from the Institute of Cancer Therapeutics at the University of Bradford in 2010, Incanthera is a UK-based specialist in dermatological cancer treatments. Products include a targeted drug delivery vector for cancer cells designed to improve treatment and minimise side effects. The latest product development, *Skin+CELL*, is a high-end cosmetic designed to deliver Vitamin B3 niacinamides which promote dermatological health and cell regeneration.

Board & Management

Chairman - Tim McCarthy

CEO - Dr Simon Ward

CFO - Laura Brogden

Company Secretary - Suzanne Brocks

Stanford Capital Partners
Research
Mike Jeremy
+44 (0) 20 3650 3650
mjeremy@stanfordcp.co.uk

Corporate Broking
Bob Pountney
+44 (0) 20 3650 3651
bpountney@stanfordcp.co.uk

ANNOUNCEMENT RE SKIN+ CELL

Incanthera has issued a statement (below) to the effect that it: “ has received unsupported allegations from a third party concerning potential patent infringement in relation to the formulation of the Skin + CELL range of products.”

Incanthera further states: “As a result, the Company is unable to launch Skin + CELL at this time. The Company has previously provided revenue and profit forecasts for its financial year ending 31 March 2025, arising from the expected sales of Skin + Cell products. As a result of the above, and the consequent delay to the launch of Skin + Cell, the Company retracts its previous market forecasts. “

Incanthera Skin + CELL statement in full

“The Company advises that it has received unsupported allegations from a third party concerning potential patent infringement in relation to the formulation of the Skin + Cell range of products.

The Company considers the unsupported allegations to be without merit. The Company is currently in communication with the third party in order to resolve this matter expediently. No formal proceedings have yet been issued, but the Company is prepared to issue related proceedings in the event that a resolution cannot be achieved swiftly.

As a result, the Company is unable to launch Skin + CELL at this time.

The Company has previously provided revenue and profit forecasts for its financial year ending 31 March 2025, arising from the expected sales of Skin + Cell products. As a result of the above, and the consequent delay to the launch of Skin + Cell, the Company retracts its previous market forecasts.

The Board of the Company is resolute in its position and remains confident for the future launch of its products. The Company will update the market further when it is in a position to do so.”

Consequently we have suspended our outlook for FY25 and forecasts pending resolution of the dispute or an update, and revised guidance from the Company concerning the status of the proposed launch of its Skin + CELL product.

DISCLAIMER

The report is a marketing communication and should not be relied upon as being an impartial or objective assessment of the subject matter and does not constitute investment research for the purposes of the Conduct of Business Sourcebook ("COBS") issued by the Financial Authority ("FCA") to reflect the requirements of the UK retained version of Regulation 600/2014/EU and the UK retained version of Directive 2014/65/EU and all rules made in connection therewith (together, known as "MIFID II"). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector. Accordingly, this report has not been prepared in accordance with legal requirements designed to promote the independence of investment research under MIFID II or otherwise and is not subject to any prohibition on dealing ahead of the dissemination of investment research. SCP may from time to time render advisory and other services to companies referred to in this report and may receive compensation for the same.

Neither the information in this report nor any opinion expressed in this report constitutes an offer by SCP to enter into any contract/agreement, nor is it a solicitation to buy or sell any investment. Nothing in this report should be deemed to constitute the provision of financial, investment or other professional advice in any way.

The content of this report is based upon sources of information believed to be reliable, however, save to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to its accuracy, completeness or correctness and SCP, its officers and employees do not accept any liability or responsibility in respect of the information or any views expressed herein or for any direct or consequential loss arising from any use of the information contained in the report.

This report may include forward-looking statements that are based upon current opinions, expectations and projections and they are not a reliable indicator of future performance. SCP undertakes no obligation to update or revise any forward-looking statements. Any references to past performances in this report are not indicative of future performance or results. Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. The value of any investment referred to in this report may go down as well as up and any amounts recovered may be less than those originally invested. When SCP comments on AIM/AQSE shares investors should be aware that because the rules for this market are less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.

This report has been designed for, is directed at and for distribution only to persons who (i) fall within article 19(1) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in COBS (issued by the FCA) of SCP (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied upon by persons in the United Kingdom who are not relevant persons and should not be distributed, in whole or in part, to any third party without the prior written consent of SCP.

Neither this report, nor any copy or part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform him or herself about and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of securities laws in the United Kingdom, the United States (or any part thereof) or any other jurisdiction in any other part of the world.

SCP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to SCP that is not reflected in this material and SCP may have acted upon or used the information prior to or immediately following its publication. In addition, SCP, directors, and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives, or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means.

Stanford Capital Partners Limited (FRN:804552) is registered in England and Wales (No 11192616) and Regulated by the Financial Conduct Authority.

Dissemination of Research: reports are made available to all relevant recipients at the same time. Issuers may, in certain circumstances, be permitted to review investment analysts' investment research prior to publication for review of factual accuracy only. Investment research prepared and disseminated by SCP is monitored to ensure that it is only provided to relevant persons. Research prepared by SCP is not intended to be received and/or used by any person who is categorised as a retail client under COBS.

STANFORD CAPITAL PARTNERS – KEY CONTACTS

RESEARCH

Mike Jeremy
+44 (0) 20 3650 3650
mjeremy@stanfordcp.co.uk

CORPORATE BROKING

Bob Pountney
+44 (0) 20 3650 3651
bpountney@stanfordcp.co.uk

Patrick Claridge
+44 (0) 20 3650 3650
pclaridge@stanfordcp.co.uk